RTTNews | Aug 16, 2021 10:00AM EDT

10:00 Monday, August 16, 2021 (RTTNews.com) - Shares of Enlivex Therapeutics Ltd. (ENLV) are surging more than 19% Monday morning after the company's drug candidate Allocetra received clearance to start Phase 2b study in severe and critical COVID-19 patients in Israel.

The he Israeli Ministry of Health has authorized the initiation after reviewing previously-reported data from the Phase 2 study.

Enlivex has earlier reported positive top-line results from Phase 1b and Phase 2 studies of Allocetra in COVID-19 patients in severe and critical condition.

ENLV, currently at $12.17, has traded in the range of $4.49- $29.40 in the past 52 weeks.

Read the original article on RTTNews ( https://www.rttnews.com/3219088/enlivex-therapeutics-rallies-19-on-getting-clearance-to-start-phase-2b-study-in-covid-19-patients.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved